Oxytocin administered intrathecally preferentially increases heart rate rather than arterial pressure in the rat.

Yashpal K, Gauthier S, Henry JL

Journal of the autonomic nervous system1 Aug 1987Cited by 36 (Europe PMC)

PMID3668162DOI10.1016/0165-1838(87)90114-7PepBankPUB-03668162

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, intrathecal oxytocin at the 9th thoracic level increased heart rate at 10 min.
In plain wordsIn rats, oxytocin given into the lower spinal cord raised heart rate at 10 minutes.
Peptide
Oxytocin
Outcome
IncreaseHeart rate, intrathecal at 9th thoracic level
Study
ratn = 14
Outcome group
Heart function · Cardiovascular
Studied dose
6.5 nmol · intrathecalAs given in this study (rat).
Measurements
Heart rate increase at 10 min
36.9 bpm
9th thoracic level
Source sentences
Summary
When administration was at the 9th thoracic level the change at 10 min was 36.9 +/- 18.0 bpm (n = 14).
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816202
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, intrathecal oxytocin at the 2nd thoracic level increased heart rate, with a maximum increase at 10 min.
In plain wordsIn rats, oxytocin given into the upper spinal cord raised heart rate, with a peak at 10 minutes.
Peptide
Oxytocin
Outcome
IncreaseHeart rate, intrathecal at 2nd thoracic level
Study
ratn = 9
Outcome group
Heart function · Cardiovascular
Studied dose
6.5 nmol · intrathecalAs given in this study (rat).
Measurements
Maximum heart rate increase at 10 min
65.4 bpm
2nd thoracic level
Source sentences
Summary
The increase in heart rate began within 1 and 5 min and reached a peak at 10-30 min; the maximum increase, at 10 min after administration, at the second thoracic level was 65.4 +/- 13.8 (S.E.M.) bpm (n = 9).
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816201
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, intravenous oxytocin caused an immediate decrease in heart rate.
In plain wordsIn rats, oxytocin given into a vein lowered heart rate straight away.
Peptide
Oxytocin
Outcome
DecreaseHeart rate, intravenous
Study
ratn = 4
Outcome group
Heart function · Cardiovascular
Studied dose
6.5 nmol · intravenousAs given in this study (rat).
Measurements
Heart rate change
−42.5 bpm
intravenous 6.5 nmol
Source sentences
Summary
When 6.5 nmol of oxytocin were administered i.v., there was an immediate decrease in heart rate by 42.5 +/- 16.5 bpm (n = 4) and an increase in systolic (6.3 +/- 6.4 mm Hg) and in diastolic (38.8 +/- 8.3 mm Hg) pressures (n = 4); this effect lasted 5-10 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816205
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, intravenous oxytocin was followed by an increase in systolic pressure of 6.3 +/- 6.4 mm Hg.
In plain wordsIn rats, oxytocin given into a vein raised systolic blood pressure.
Peptide
Oxytocin
Outcome
IncreaseSystolic pressure, intravenous
Study
ratn = 4
Outcome group
Blood pressure · Cardiovascular
Studied dose
6.5 nmol · intravenousAs given in this study (rat).
Measurements
Systolic pressure change
6.3 mm Hg
intravenous 6.5 nmol
Source sentences
Summary
When 6.5 nmol of oxytocin were administered i.v., there was an immediate decrease in heart rate by 42.5 +/- 16.5 bpm (n = 4) and an increase in systolic (6.3 +/- 6.4 mm Hg) and in diastolic (38.8 +/- 8.3 mm Hg) pressures (n = 4); this effect lasted 5-10 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816206
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, intravenous oxytocin increased diastolic pressure; the effect lasted 5-10 min.
In plain wordsIn rats, oxytocin given into a vein raised diastolic blood pressure for 5-10 minutes.
Peptide
Oxytocin
Outcome
IncreaseDiastolic pressure, intravenous
Study
ratn = 4
Outcome group
Blood pressure · Cardiovascular
Studied dose
6.5 nmol · intravenousAs given in this study (rat).
Measurements
Diastolic pressure change
38.8 mm Hg
intravenous 6.5 nmol
Source sentences
Summary
When 6.5 nmol of oxytocin were administered i.v., there was an immediate decrease in heart rate by 42.5 +/- 16.5 bpm (n = 4) and an increase in systolic (6.3 +/- 6.4 mm Hg) and in diastolic (38.8 +/- 8.3 mm Hg) pressures (n = 4); this effect lasted 5-10 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816207
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, intrathecal oxytocin had no effect on arterial pressure.
In plain wordsIn rats, oxytocin given into the spinal cord did not change arterial blood pressure.
Peptide
Oxytocin
Outcome
No significant changeArterial pressure, intrathecal
Study
ratn: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
6.5 nmol · intrathecalAs given in this study (rat).
Source sentences
Summary
This increased heart rate but had no effect on arterial pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816203
07AnimalAnimal study (in vivo)Efficacy outcome
In rats, 1.625 nmol of intrathecal oxytocin at the 9th thoracic level had a qualitatively similar effect to the higher dose, but smaller and with a more delayed onset.
In plain wordsIn rats, a lower dose of oxytocin in the spinal cord had a similar but smaller and later effect than the higher dose.
Peptide
Oxytocin
Outcome
IncreaseHeart rate, intrathecal 1.625 nmol
Study
ratn: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
1.625 nmol · intrathecalAs given in this study (rat).
Source sentences
Summary
Administration of 1.625 nmol of oxytocin at the 9th thoracic level had an effect qualitatively similar to that seen with the higher dose, but the response was smaller in magnitude and more delayed in onset
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816208
08AnimalAnimal study (in vivo)Efficacy outcome
In rats, 0.65 nmol of oxytocin was without effect.
In plain wordsIn rats, the lowest oxytocin dose tested had no effect.
Peptide
Oxytocin
Outcome
No significant changeResponse to intrathecal 0.65 nmol
Study
ratn: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
0.65 nmol · intrathecalAs given in this study (rat).
Source sentences
Summary
0.65 nmol of oxytocin were without effect.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816209
09AnimalAnimal study (in vivo)Pharmacokinetics
In rats, after intrathecal [125I]oxytocin, the blood level reached a maximum of 0.6% of the total injected dose by 30 min.
In plain wordsIn rats, only a small share of oxytocin given into the spinal cord reached the blood, at most 0.6% by 30 minutes.
Peptide
Oxytocin
Outcome
Not applicableTransfer of [125I]oxytocin to blood after intrathecal administration
Study
ratn: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intrathecalAs given in this study (rat).
Measurements
Maximum blood level
0.6 % of injected dose
30 min after administration
Source sentences
Summary
Transfer of label to the blood after intrathecal administration of [125I]oxytocin indicated that the level in the blood reached a maximum of 0.6% of the total injected by 30 min after administration.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
Report a problemFND-0366816210

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

10AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism
In rats, systemic hexamethonium, a blocker of nicotinic transmission in autonomic ganglia, prevented the heart rate increase caused by intrathecal oxytocin.
In plain wordsIn rats, a drug that blocks ganglion signalling stopped the heart rate rise caused by oxytocin in the spinal cord.
Peptide
Oxytocin
Outcome
DecreaseCardioacceleration after hexamethonium
Study
ratn: not reported in source
Comparator
Intrathecal oxytocin without hexamethonium
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Administration of hexamethonium systematically, to block nicotinic transmission in autonomic ganglia, prevented the cardioacceleration in response to intrathecal administration of oxytocin.
1 context sentence(design, population, supporting numbers)
Summary · context
Oxytocin was administered intrathecally at a dose of 6.5 nmol to the 9th or 2nd thoracic level of the spinal cord in the rat.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0366816204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:52 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.